These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? Remon J; Besse B; Soria JC BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592 [TBL] [Abstract][Full Text] [Related]
5. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132 [TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
7. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577 [TBL] [Abstract][Full Text] [Related]
9. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Sgambato A; Casaluce F; Gridelli C Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698 [TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Lung Cancer. Du L; Herbst RS; Morgensztern D Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Chen YM J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Remon J; Besse B Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852 [TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? Ramamurthy C; Godwin JL; Borghaei H Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Morgensztern D; Herbst RS Clin Cancer Res; 2016 Aug; 22(15):3713-7. PubMed ID: 27252413 [TBL] [Abstract][Full Text] [Related]
19. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515 [TBL] [Abstract][Full Text] [Related]
20. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. Villaruz LC; Socinski MA Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]